• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir.在2例对多替拉韦基线部分敏感的经治个体中，随着T97A突变的出现，对多替拉韦的高水平耐药迅速发展。
Open Forum Infect Dis. 2018 Sep 8;5(10):ofy221. doi: 10.1093/ofid/ofy221. eCollection 2018 Oct.
2
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy.高水平的多替拉韦耐药性可迅速由少数变异体产生，并通过重组传播：对整合酶链转移抑制剂挽救治疗的影响。
AIDS. 2022 Nov 1;36(13):1835-1840. doi: 10.1097/QAD.0000000000003288. Epub 2022 Jul 9.
3
Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.临床观察到的 HIV 整合酶突变组合对整合酶链转移抑制剂（INSTIs）表型耐药性的影响：一项分子研究。
J Antimicrob Chemother. 2022 Mar 31;77(4):979-988. doi: 10.1093/jac/dkab498.
4
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.预先存在的T97A HIV-1整合酶突变对整合酶链转移抑制剂耐药性和治疗结果缺乏影响。
PLoS One. 2017 Feb 17;12(2):e0172206. doi: 10.1371/journal.pone.0172206. eCollection 2017.
5
In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.多替拉韦对野生型和整合酶抑制剂耐药HIV-2的体外活性。
Retrovirology. 2015 Feb 5;12:10. doi: 10.1186/s12977-015-0146-8.
6
Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.HIV-1 链转移整合酶抑制剂卡博特韦耐药的基因型相关性。
Antiviral Res. 2022 Dec;208:105427. doi: 10.1016/j.antiviral.2022.105427. Epub 2022 Sep 30.
7
The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.HIV-1整合酶中R263K和T66I耐药性替代的组合与高水平病毒复制及高水平耐药性的发展不相容。
J Virol. 2015 Nov;89(22):11269-74. doi: 10.1128/JVI.01881-15. Epub 2015 Aug 26.
8
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.在 IMPAACT P1093 研究中，来自儿科人群的 HIV-1 整合酶对多替拉韦治疗的耐药性出现。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164521. doi: 10.1128/AAC.01645-21. Epub 2021 Oct 25.
9
Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.对基于整合酶抑制剂（INSTI）方案治疗失败的、有高度治疗经验的患者对 HIV-1 整合酶链转移抑制剂（INSTIs）的敏感性。
Int J Antimicrob Agents. 2020 Jul;56(1):106027. doi: 10.1016/j.ijantimicag.2020.106027. Epub 2020 May 23.
10
Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.整合酶抑制剂耐药突变的积累赋予了来自乌干达因拉替拉韦治疗失败的非 B 亚型 HIV-1 患者对多替拉韦的高水平耐药性。
J Antimicrob Chemother. 2020 Dec 1;75(12):3525-3533. doi: 10.1093/jac/dkaa355.

引用本文的文献

1
Computational and Population-Based HLA Permissiveness to HIV Drug Resistance-Associated Mutations.基于计算和人群的HLA对HIV耐药相关突变的允许性
Pathogens. 2025 Feb 20;14(3):207. doi: 10.3390/pathogens14030207.
2
Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants.第二代整合酶链转移抑制剂（INSTIs）与研发中的化合物4d对一组整合酶四重突变体的抗病毒效力的比较分析。
Viruses. 2025 Jan 16;17(1):121. doi: 10.3390/v17010121.
3
Population dynamics of HIV drug resistance during treatment scale-up in Uganda: a population-based longitudinal study.乌干达扩大治疗期间艾滋病毒耐药性的人群动态：一项基于人群的纵向研究。
medRxiv. 2024 Oct 9:2023.10.14.23297021. doi: 10.1101/2023.10.14.23297021.
4
HIV transmission dynamics and population-wide drug resistance in rural South Africa.HIV 传播动态和南非农村地区的全人群耐药性。
Nat Commun. 2024 Apr 29;15(1):3644. doi: 10.1038/s41467-024-47254-z.
5
Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.初治人类免疫缺陷病毒 1 型整合酶抑制剂人群中出现的治疗中出现的多替拉韦耐药突变：快速范围界定综述。
Viruses. 2023 Sep 15;15(9):1932. doi: 10.3390/v15091932.
6
HIV drug resistance monitoring in the era of dolutegravir and injectable long-acting cabotegravir in resource-limited settings.在资源有限的环境中，多替拉韦时代及注射用长效卡博特韦的HIV耐药性监测
AIDS. 2023 Aug 1;37(10):1629-1631. doi: 10.1097/QAD.0000000000003600.
7
Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania.坦桑尼亚一线和二线抗逆转录病毒治疗失败的整合酶抑制剂初治患者中对整合酶抑制剂的原发耐药。
J Antimicrob Chemother. 2022 Oct 28;77(11):3138-3143. doi: 10.1093/jac/dkac295.
8
Exploring the mechanisms behind HIV drug resistance in sub-Saharan Africa: conceptual mapping of a complex adaptive system based on multi-disciplinary expert insights.探索撒哈拉以南非洲地区 HIV 耐药性背后的机制：基于多学科专家见解的复杂适应系统的概念映射。
BMC Public Health. 2022 Mar 7;22(1):455. doi: 10.1186/s12889-022-12738-4.
9
HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana.博茨瓦纳在接受联合抗逆转录病毒治疗（ART）时低病毒血症个体中的 HIV-1 耐药突变。
J Antimicrob Chemother. 2022 Apr 27;77(5):1385-1395. doi: 10.1093/jac/dkac056.
10
HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.博茨瓦纳接受基于整合酶链转移抑制剂方案治疗失败的重度治疗患者中的 HIV-1 亚型 C 耐药突变。
Viruses. 2021 Mar 31;13(4):594. doi: 10.3390/v13040594.

本文引用的文献

1
HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.对耐药突变广泛有效的 HIV-1 整合酶抑制剂。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.01035-18. Print 2018 Sep.
2
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).含多替拉韦（DTG）方案治疗接受拉替拉韦（RAL）或艾维雷韦（EVG）后的病毒学反弹：意大利大型 HIV 耐药性网络（ARCA）中的持久性和病毒学应答。
J Clin Virol. 2018 Aug;105:112-117. doi: 10.1016/j.jcv.2018.06.012. Epub 2018 Jun 21.
3
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).埃替拉韦仑/考比司他/恩曲他滨/替诺福韦酯与阿扎那韦+利托那韦+恩曲他滨/替诺福韦酯在HIV-1感染女性中的第48周耐药性分析（WAVES研究GS-US-236-0128）
HIV Clin Trials. 2017 Jul;18(4):164-173. doi: 10.1080/15284336.2017.1370059.
4
Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.基于结构导向的HIV整合酶链转移抑制剂优化
J Med Chem. 2017 Sep 14;60(17):7315-7332. doi: 10.1021/acs.jmedchem.7b00596. Epub 2017 Aug 10.
5
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.预先存在的T97A HIV-1整合酶突变对整合酶链转移抑制剂耐药性和治疗结果缺乏影响。
PLoS One. 2017 Feb 17;12(2):e0172206. doi: 10.1371/journal.pone.0172206. eCollection 2017.
6
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.比克替拉韦（GS-9883）的抗病毒活性，一种新型强效HIV-1整合酶链转移抑制剂，具有改善的耐药性谱。
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. doi: 10.1128/AAC.01474-16. Print 2016 Dec.
7
Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients.多替拉韦功能单药疗法对整合酶链转移抑制剂耐药患者的HIV-1病毒学应答的影响。
Antivir Ther. 2016;21(6):481-488. doi: 10.3851/IMP3033. Epub 2016 Feb 11.
8
Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.新型通路致携带 N155H 及多种耐药突变患者对多替拉韦耐药的演变。
J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3.
9
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.原发性依维菌素耐药相关突变对 HIV-1 整合酶的药物敏感性和病毒复制适应性的影响。
Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.
10
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.多替拉韦治疗经拉替拉韦耐药的 HIV-1 感染治疗经验丰富的受试者中的安全性和疗效：VIKING 研究的 24 周结果。
J Infect Dis. 2013 Mar 1;207(5):740-8. doi: 10.1093/infdis/jis750. Epub 2012 Dec 7.

在2例对多替拉韦基线部分敏感的经治个体中，随着T97A突变的出现，对多替拉韦的高水平耐药迅速发展。

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir.

作者信息

George Jomy M, Kuriakose Safia S, Dee Nicola, Stoll Pam, Lalani Tahaniyat, Dewar Robin, Khan Muhammad A, Rehman Muhammad T, Grossman Zehava, Maldarelli Frank, Pau Alice K

机构信息

Clinical Center, National Institutes of Health, Bethesda, Maryland.

Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland.

出版信息

Open Forum Infect Dis. 2018 Sep 8;5(10):ofy221. doi: 10.1093/ofid/ofy221. eCollection 2018 Oct.

DOI:10.1093/ofid/ofy221
PMID:30568974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6172925/
Abstract

HIV integrase mutation T97A emerges after suboptimal therapy with integrase strand transfer inhibitors (INSTIs), but the contribution of T97A to dolutegravir resistance remains uncertain. Here we report >10-fold increase in dolutegravir resistance after the single addition of T97A in 2 individuals with prior INSTI resistance receiving dolutegravir salvage therapy.

摘要

在使用整合酶链转移抑制剂（INSTIs）进行次优治疗后出现了HIV整合酶突变T97A，但T97A对多替拉韦耐药性的影响仍不确定。在此，我们报告，在2例先前对INSTIs耐药且接受多替拉韦挽救治疗的患者中，单独添加T97A后，多替拉韦耐药性增加了10倍以上。